[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100548851":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":30,"centralContacts":38,"locations":10,"responsibleParty":47,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":68,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":10},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Group I",null,"HF with reduced ejection fraction (HFrEF, LVEF ≤ 40%)",[13],"Diagnostic Test: ST2",{"label":15,"type":10,"description":16,"interventionNames":17},"Group II","HF with mildly reduced ejection fraction (HFmrEF, LVEF 41-49%)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Group III","HF with preserved ejection fraction (HFpEF, LVEF ≥ 50%)",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DIAGNOSTIC_TEST","ST2","ELISA used to detect levels of ST2 and BNP as inflammatory biomarkers in patients with heart failure",[9,15,19],[29],"BNP",[31,34,36],{"name":32,"affiliation":5,"role":33},"Randa Ahmed","STUDY_DIRECTOR",{"name":35,"affiliation":5,"role":33},"Hanan Omer",{"name":37,"affiliation":5,"role":33},"Yousra Mamdouh",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":10,"email":43},"Dalia Hesham","CONTACT","01149936172","daliahesham1771993@gmail.com",{"name":45,"role":41,"phone":46,"phoneExt":10,"email":10},"randa ahmed","01003390690",{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Dalia Mohamed Hesham Ahmed Mohamed","doctor","100548851","soluble-st2-in-patients-with-heart-failure-100548851",false,"NCT06426368","Soluble ST2 in Patients With Heart Failure\"","\" Prognostic Value of Soluble ST2 Beyond B-Type Natriuretic Peptide in Management of Patients With Heart Failure\"","Inclusion Criteria:\n\n* patients 18-80 years.\n* Both sexes will be included.\n* including signs and symptoms of HF (e.g., elevated jugular venous pressure and altered apical beat position), altered LVEF (\\\u003C 40%; 40%-49%; ≥ 50%)\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years\n* Patients with documented evidence of cardiogenic shock .\n* Patients with Acute coronary syndrome within 30 days.\n* chronic kidney disease patients with glomerular filtration rate \\\u003C 30\n* Patients with interstitial pulmonary fibrosis .","ALL","18 Years","80 Years",{"count":62,"type":63},100,"ESTIMATED","OBSERVATIONAL","1. The aim of this study was to explore the relationship between peripheral circulating serum soluble suppression of tumorigenicity-2 (sST2) levels and inflammatory biomarkers in patients with heart failure\n2. Additive role of sST2 to NPs in of heart failure patients",[67],"Heart Failure Patients","NOT_YET_RECRUITING","2024-05-17",{"date":71,"type":72},"2024-05-23","ACTUAL",{"date":74,"type":63},"2024-07-01",{"date":76,"type":63},"2027-01-01",{"name":5,"class":6}]